CA2360800A1 - Inhibition du chemin de presentation de l'antigene du complexe majeur d'histocompatibilite de classe ii et presentation aux cellules cd4+ - Google Patents

Inhibition du chemin de presentation de l'antigene du complexe majeur d'histocompatibilite de classe ii et presentation aux cellules cd4+ Download PDF

Info

Publication number
CA2360800A1
CA2360800A1 CA002360800A CA2360800A CA2360800A1 CA 2360800 A1 CA2360800 A1 CA 2360800A1 CA 002360800 A CA002360800 A CA 002360800A CA 2360800 A CA2360800 A CA 2360800A CA 2360800 A1 CA2360800 A1 CA 2360800A1
Authority
CA
Canada
Prior art keywords
protein
cells
vector
mhc
class
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002360800A
Other languages
English (en)
Inventor
David C. Johnson
Roman Tomazin
Jessica Boname
Nagendra R. Hegde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health Science University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2360800A1 publication Critical patent/CA2360800A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La protéine du cytomégalovirus humain, qui s'est déjà avérée capable de bloquer le chemin de présentation de l'antigène du complexe majeur d'histocompatibilité (CMH) de classe I, s'est ici avérée capable de bloquer le chemin de présentation du CMH de classe II. Cela est surprenant car les protéines de classe I et de classe II ne sont pas homologues. La protéine US2 provoque la dégradation de protéines alpha de classe II et également de protéines DM-alpha de classe II, partie d'un complexe enzymatique nécessaire au chargement de peptides antigéniques. En ce sens, la protéine US2 a un double effet inhibiteur sur le chemin du CMH de classe II. L'expression de US2 bloque efficacement la présentation d'antigènes aux lymphocytes T CD4+. La protéine US2 ou des variantes solubles de cette dernière peuvent être utilisées pour réduire des réponses immunitaires inappropriées dirigées contre des vecteurs ou des transgènes exprimés. De plus, de telles molécules peuvent être utilisées pour bloquer l'immunité vis-à-vis de cellules ou d'organes transplantés ou lors de maladies auto-immunes.
CA002360800A 1999-02-02 2000-02-02 Inhibition du chemin de presentation de l'antigene du complexe majeur d'histocompatibilite de classe ii et presentation aux cellules cd4+ Abandoned CA2360800A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11828799P 1999-02-02 1999-02-02
US60/118,287 1999-02-02
PCT/US2000/002740 WO2000046361A1 (fr) 1999-02-02 2000-02-02 Inhibition du chemin de presentation de l'antigene du complexe majeur d'histocompatibilite de classe ii et presentation aux cellules cd4+

Publications (1)

Publication Number Publication Date
CA2360800A1 true CA2360800A1 (fr) 2000-08-10

Family

ID=22377657

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002360800A Abandoned CA2360800A1 (fr) 1999-02-02 2000-02-02 Inhibition du chemin de presentation de l'antigene du complexe majeur d'histocompatibilite de classe ii et presentation aux cellules cd4+

Country Status (4)

Country Link
EP (1) EP1157102A4 (fr)
AU (1) AU2752900A (fr)
CA (1) CA2360800A1 (fr)
WO (1) WO2000046361A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100789845B1 (ko) 2005-04-07 2007-12-28 (주)엠젠 세포성 면역 억제를 위한 ｕｓ2 단백질을 발현하는 돼지클론 체세포주의 제조 방법
US20120022337A1 (en) * 2010-07-26 2012-01-26 Searete Llc MHC-less cells
KR101263103B1 (ko) * 2011-01-18 2013-05-09 고려대학교 산학협력단 ＣＤ１ｄ 발현을 감소조절하는 ＵＳ２ 단백질 유전자를 포함하는 자연 살해 Ｔ 세포활성 억제용 조성물 및 이를 이용한 자연 살해 Ｔ 세포 활성 억제 방법
GB202019879D0 (en) * 2020-12-16 2021-01-27 Ucl Business Ltd Polypeptide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202426A (en) * 1988-11-02 1993-04-13 Marine Biological Laboratory Eucaryotic NAD cyclases
US5846806A (en) * 1994-07-29 1998-12-08 American Cyanamid Company Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression
WO1997032605A1 (fr) * 1996-03-08 1997-09-12 Massachusetts Institute Of Technology Acides nucleiques de cytomegalovirus codant pour des proteines ayant une liaison mhc de classe i normale ou modifiee et utilises dans le traitement de certaines maladies

Also Published As

Publication number Publication date
EP1157102A4 (fr) 2004-07-14
AU2752900A (en) 2000-08-25
EP1157102A1 (fr) 2001-11-28
WO2000046361A1 (fr) 2000-08-10

Similar Documents

Publication Publication Date Title
Cashman et al. A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration
Salghetti et al. Human immunodeficiency virus type 1 Nef and p56lck protein-tyrosine kinase interact with a common element in CD4 cytoplasmic tail.
US11787849B2 (en) Methods and compounds for eliminating immune responses to therapeutic agents
US9861661B2 (en) Elimination of immune responses to viral vectors
Kopfler et al. Adenovirus-mediated transfer of a gene encoding human apolipoprotein AI into normal mice increases circulating high-density lipoprotein cholesterol.
JP2021502058A (ja) Ｒｎａを編集するための組成物および方法
JP2007289206A (ja) 複製欠陥組換えレトロウィルス
NO316744B1 (no) Sammensetning for innforing av nukleinsyrekomplekser i hoyere eukaryotiske celler, kompleks, endosomolytisk peptid, fremgangsmater og transfeksjonssett
JPH10506008A (ja) ＨＩＶ−１ Ｖｐｒ 融合分子に基づいたＨＩＶビリオン中へのタンパク質ターゲッティング
KR100472938B1 (ko) 세포침투 효율을 향상시킨 수송도메인-목표단백질-수송도메인 융합단백질 및 그 용도
JPH11505128A (ja) キメラインテグラーゼタンパク質に媒介される真核生物ゲノム中へのベクター構築物の位置特異的組み込み
MX2011007263A (es) Gen que codifica para mutante de glucocinasa humana, enzima codificada por el mismo, vectores y hospederos recombinantes, composiciones farmaceuticas y usos de los mismos, y métodos para tratar y prevenir enfermedades.
JP2006520604A (ja) ＣＤ８α鎖に基づき免疫原性が減少した遺伝子治療ベクター
JP2006320331A (ja) 後天性疾患治療用の新規移植組織片および新規ベクター
EP0689586B1 (fr) Activite et fonction de la proteine virale r
CA2360800A1 (fr) Inhibition du chemin de presentation de l'antigene du complexe majeur d'histocompatibilite de classe ii et presentation aux cellules cd4+
US6156306A (en) Pancreatic β-cells for allogeneic transplantation without immunosuppression
US20230101788A1 (en) Gene therapy
EP1545602B1 (fr) Compositions pharmaceutiques renfermant une proteine d'enveloppe du vih et cd4
US7608449B2 (en) Methods and compositions related to high-titer pseudotyped retroviruses
EP1045920A1 (fr) Systemes d'expression nucleotidiques a immunogenicite reduite destines a la therapie genique
WO1999003999A1 (fr) Procedes et compositions servant a inhiber la reaction proinflammatoire
JP2002537809A (ja) 平滑筋細胞の増殖を阻害するための方法および試薬
KR100241685B1 (ko) 핵산 복합체를 고등 진핵세포내로 도입시키기 위한 조성물
Willemsen Improving adenoviral vectors for muscle-directed gene therapy.

Legal Events

Date Code Title Description
FZDE Dead